Table 4 Minimally adjusted and adjusted Cox models of breast cancer mortality in complete case and imputed cohort.

From: Breast cancer survival and mortality among women with type 2 diabetes: a retrospective cohort study

 

Minimally adjusted complete case (95% CI)

Adjusted complete case (95% CI)

Minimally adjusted imputed (95% CI)

Adjusted imputed (95% CI)

Subtypes

Luminal A

Ref

Ref

Ref

Ref

Luminal B (HER2-)

1.85 (1.31, 2.61)

2.04 (1.43, 2.90)

1.81 (1.36, 2.42)

1.92 (1.40, 2.62)

Luminal B (HER2 +)

2.83 (1.89, 4.23)

2.22 (1.46, 3.38)

2.38 (1.66, 3.42)

2.16 (1.46, 3.18)

HER2-enriched

5.82 (3.91, 8.66)

2.93 (1.63, 5.27)

4.68 (3.26, 6.72)

1.71 (1.01, 2.89)

TNBC

6.28 (4.63, 8.53)

5.68 (3.40, 9.50)

4.70 (3.58, 6.17)

2.74 (1.72, 4.37)

Age at BC diagnosis

50–69 years

Ref

Ref

Ref

Ref

70–84 years

2.19 (1.72, 2.79)

1.19 (0.88, 1.60)

2.08 (1.69, 2.55)

1.17 (0.91, 1.50)

Year of BC diagnosis

2010–2013

Ref

Ref

Ref

Ref

2014–2016

0.85 (0.64, 1.14)

0.81 (0.60, 1.08)

0.82 (0.65, 1.04)

0.81 (0.64, 1.03)

2017–2019

0.94 (0.72, 1.24)

0.78 (0.58, 1.03)

0.84 (0.65, 1.05)

0.81 (0.63, 1.02)

Mode of detection

Screen-detected

Ref

Ref

Ref

Ref

Non-screen-detected

5.24 (3.42, 8.02)

2.52 (1.62, 3.92)

4.83 (3.38, 6.89)

1.80 (1.24, 2.62)

Surgery

Yes

Ref

Ref

Ref

Ref

No

11.37 (8.74, 14.78)

14.02 (10.52, 18.69)

9.86 (7.89, 12.33)

14.06 (10.83, 18.24)

Chemotherapy

Yes

Ref

Ref

Ref

Ref

No

0.40 (0.31, 0.53)

0.71 (0.51, 0.97)

0.45 (0.35, 0.56)

0.75 (0.57, 0.99)

Radiotherapy

Yes

Ref

Ref

Ref

Ref

No

1.83 (1.44, 2.32)

0.71 (0.53, 0.93)

2.25 (1.82, 2.77)

0.83 (0.65, 1.06)

Hormone therapy

Yes

Ref

Ref

Ref

Ref

No

3.62 (2.86, 4.58)

4.15 (3.16, 5.44)

3.57 (2.93, 4.35)

3.20 (2.19, 4.69)

SIMD quintile

5 (least deprived)

Ref

Ref

Ref

Ref

4

0.74 (0.49, 1.12)

0.79 (0.52, 1.20)

0.84 (0.67, 1.06)

0.94 (0.75, 1.19)

3

0.81 (0.54, 1.22)

0.93 (0.61, 1.40)

0.88 (0.70, 1.12)

0.99 (0.77, 1.26)

2

1.00 (0.69, 1.46)

0.90 (0.61, 1.31)

1.11 (0.89, 1.38)

0.98 (0.78, 1.24)

1 (most deprived)

1.04 (0.71, 1.53)

0.85 (0.58, 1.26)

1.25 (0.99, 1.59)

1.15 (0.90, 1.46)

Scottish region

West

Ref

Ref

Ref

Ref

North

0.88 (0.65, 1.19)

0.77 (0.56, 1.06)

0.77 (0.60, 1.00)

0.86 (0.66, 1.12)

Southeast

1.11 (0.85, 1.44)

0.91 (0.69, 1.21)

0.93 (0.74, 1.17)

1.12 (0.88, 1.42)

T2DM duration

 < 5

Ref

Ref

Ref

Ref

5–9

1.04 (0.76, 1.44)

0.99 (0.72, 1.36)

0.96 (0.73, 1.25)

1.01 (0.77, 1.32)

10–14

0.92 (0.64, 1.33)

0.79 (0.55, 1.15)

0.88 (0.65, 1.18)

0.78 (0.57, 1.06)

15–19

1.54 (1.05, 2.27)

1.14 (0.77, 1.68)

1.34 (0.97, 1.87)

1.15 (0.82, 1.61)

 ≥ 20

1.09 (0.76, 1.57)

0.91 (0.63, 1.33)

0.99 (0.74, 1.34)

0.89 (0.66, 1.22)

  1. Cox models indicate breast cancer mortality (with 95% CI) up to three years after breast cancer diagnosis, among women with type 2 diabetes and a breast cancer diagnosis in Scotland between 2010 and 2019.
  2. Minimally adjusted models: age at breast cancer diagnosis, year of diagnosis, Scottish region.
  3. Adjusted models: age at breast cancer diagnosis, year of diagnosis, Scottish region, mode of detection, treatments (surgery, chemotherapy, radiotherapy, hormone therapy), SIMD quintile and T2DM duration.
  4. BC breast cancer, TNBC triple negative breast cancer, HER2 human epidermal growth factor 2, CI confidence interval, T2DM type 2 diabetes mellitus, SIMD Scottish index of multiple deprivation, Ref reference category.
Back to article page